Robert L. Ferrara - 11 Sep 2025 Form 4/A - Amendment Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Reporting relationship: Director
Issuer ticker: PHIO
Reported as of: 11 Sep 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 15 Sep 2025, 16:02:03 UTC
Original report date: 15 Sep 2025
Prior SEC filing: 11 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Lisa C. Carson, Attorney-in-fact

Key filing fact

Robert L. Ferrara filed Form 4/A - Amendment for Phio Pharmaceuticals Corp. (PHIO) on 15 Sep 2025.

Key facts

This page summarizes Robert L. Ferrara's Form 4/A - Amendment filing for Phio Pharmaceuticals Corp. (PHIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Sep 2025, 16:02.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001792987 Primary reporting owner

Ferrara Robert L

Relationship: Director
Address: C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA
Signature: /s/ Lisa C. Carson, Attorney-in-fact
Signature date: 15 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHIO transaction

Common Stock, $.0001 par value

Award

Transaction value: $0
Shares: +23,100
Change %: +147%
Price: $0.000000
Shares after: 38,766
Date: 11 Sep 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.

Footnote F2

Includes shares of common stock underlying unvested restricted stock units.

Footnote F3

The number of reported securities has been adjusted to reflect prior reverse stock splits.

Footnote F4

This amended Form 4 corrects the number of stock options reported in the original Form 4 filed on September 15, 2025. The original filing incorrectly stated that 23,000 restricted stock units were granted. The correct number of restricted stock units granted was 23,100. Securities beneficially owned changed from 38,666 to 38,766.